Gastroenterology
Guideline
Apr 2021
For professionals
An international expert agreement on what 'treat to target' should aim for in IBD. Short-term goals are feeling better and getting blood and poo inflammation tests back to normal. Long-term goals include a healed bowel lining seen at endoscopy, no disability, a normal quality of life, and normal growth in children. Healing through the full bowel wall in Crohn's is not yet a formal target but is a sign of deeper remission.
Topics
Monitoring
Research
Medicines
Jargon explained
treat to target
endoscopic healing
transmural healing
biomarker
calprotectin
CRP
clinical remission
Gastroenterology
Study
Jan 2007
Patients and professionals
The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.
Topics
Biologics and newer medicines
Jargon explained
maintenance
remission
CDAI
placebo
Gastroenterology
Study
Mar 2007
Patients and professionals
The key trial of infliximab in 112 children with moderate to severe Crohn's. After the first three doses, 88% had improved and 59% were in remission. Children given the drug every 8 weeks afterwards did better at one year than those given it every 12 weeks. It led to infliximab being used for children.
Topics
Children and young people
Biologics and newer medicines
Jargon explained
induction
maintenance
clinical response
PCDAI
NHS inform (Scotland)
Web page
For patients
Scotland's national health information page on Crohn's. It explains that inflammation can occur anywhere from mouth to back passage but is most common in the last part of the small intestine or the colon, that it is usually diagnosed between 15 and 40, and lists common and less common symptoms, remission and flare-ups.
Topics
About Crohn's disease
Symptoms
Jargon explained
ileum
colon
remission
flare-up
NICE
Web page
May 2019
For patients
A plain-English version of NICE's Crohn's guideline written for patients and families. It describes Crohn's as a lifelong condition whose symptoms flare and settle, explains that treatment aims to keep symptoms under good control, and sets out what care you should expect from the NHS.
Topics
About Crohn's disease
Living well
Jargon explained
flare-up
remission
Cochrane
Systematic review
Feb 2019
Patients and professionals
A Cochrane review of 18 trials that tested cutting down or cutting out foods thought to provoke IBD symptoms. The authors found the evidence too weak to say whether any of these diets help bring on or keep remission, and called for better trials. This summary dates from 2019.
Topics
Diet and nutrition
Research
Jargon explained
remission
exclusion diet
randomised controlled trial
British Society of Gastroenterology
Guideline
Jun 2025
For professionals
The current UK specialist guideline for managing IBD in adults, replacing the 2019 version. It is designed to sit alongside the IBD Standards and encourage use of the national primary care pathway for lower gut symptoms so diagnosis is quicker and more accurate. Among its general principles, it recommends classifying Crohn's using the Montreal system.
Topics
About Crohn's disease
Diagnosis and tests
Medicines
Monitoring
Complications
Surgery
Jargon explained
Montreal classification
remission
endoscopic remission
inflammatory bowel disease
advanced therapy
GRADE
induction
maintenance
The Lancet
Study
May 2022
For professionals
The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.
Topics
Biologics and newer medicines
Research
Jargon explained
IL-23
maintenance
placebo
endoscopic response
MDCalc
Tool
For professionals
An online CDAI calculator. It shows that the CDAI needs a 7-day symptom diary, body weight and a blood test result, and explains that a score under 150 is a marker of remission and over 450 a marker of severe Crohn's.
Topics
Monitoring
Research
Jargon explained
Crohn's Disease Activity Index
haematocrit
remission
NHS
Web page
For patients
The NHS page on ulcerative colitis, the other main type of IBD, which inflames the large bowel and rectum rather than anywhere in the gut. It describes the typical symptoms, such as bloody diarrhoea and a frequent, urgent need to poo, and explains flare-ups and remission. Useful for comparing UC with Crohn's.
Topics
About Crohn's disease
Symptoms
Flare-ups
Jargon explained
ulcerative colitis
colon
rectum
flare-up
remission
North Bristol NHS Trust
Leaflet
Feb 2026
For patients
A dietitians' leaflet for adults on EEN, a liquid-only diet used for a few weeks to calm Crohn's or reduce symptoms. It explains that prescribed drinks replace all food and most drinks while providing everything you need.
Topics
Diet and nutrition
Jargon explained
exclusive enteral nutrition
remission
flare-up
The Lancet Gastroenterology & Hepatology
Study
May 2024
Patients and professionals
A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.
Topics
Biologics and newer medicines
Research
About Crohn's disease
Jargon explained
top-down treatment
step-up treatment
biomarker
steroid-free remission
top-down
step-up
immunomodulator
randomised controlled trial